Core Viewpoint - The company Jiangyin Beirisen Biochemical Technology Co., Ltd. is leading the development of mussel adhesive protein for medical applications, having recently completed a new round of equity financing to accelerate clinical development of its products [1] Group 1: Original Research Breakthroughs - Mussel adhesive protein, extracted from mussels, is recognized for its anti-inflammatory and immune barrier reconstruction properties, earning it the title of "marine soft gold" [3] - Beirisen is the first company globally to apply mussel adhesive protein in the medical field, establishing a full industry chain from laboratory research to market commercialization since its founding in January 2011 [5] Group 2: New Medical Aesthetic Injection Market - Beirisen has overcome three major global challenges in the production of mussel adhesive protein: purification difficulty, high costs, and storage at room temperature [7] - The company has successfully purified mussel adhesive protein to over 70% medical-grade standards and achieved a three-year room temperature storage capability [7] - Beirisen has filed over 100 patents covering the entire process from raw material preparation to clinical application, with its Class III medical device for intradermal injection showing significant efficacy in anti-inflammatory repair and wound healing [7] Group 3: Capital and Industry Dual-Drive - The recent financing will focus on three main areas: accelerating clinical transformation of multiple product lines, building a closed-loop full industry chain, and deepening international research cooperation [11] - Beirisen aims to establish its own GMP-standard production workshop and cold chain logistics system to control the entire process from raw material preparation to end products [11] - The company is transitioning from a regional innovative enterprise to a globally competitive original manufacturer of biomaterials, expanding the application of mussel adhesive protein from single applications to multi-scenario medical solutions [11]

Group 1 - The core point of the article is that Jiangyin Beirisen Biochemical Technology Co., Ltd. has successfully completed a new round of financing, led by Honghui Fund, with Luhua Investment participating, and Kunquan Capital serving as the financial advisor [1] - The funds from this financing round will primarily be used for the clinical development of biomedical materials based on mussel adhesive protein, specifically for Class III medical devices and chronic wound care products, enhancing Beirisen's competitive edge as a global original manufacturer of mussel adhesive protein [1] - Beirisen was established in 2011 and focuses on the development of macromolecular original raw materials centered on mussel adhesive protein, aiming for medical research, industrial development, and commercialization, thus forming a complete industry chain from laboratory to market [1] Group 2 - The company was co-founded by Dr. Gu Ming from the Chinese Academy of Sciences and Jan-Christer Janson, an internationally renowned expert in protein separation and purification, who received the 2015 International Science and Technology Cooperation Award of the People's Republic of China [1] - The company has appointed Nobel Prize winner Bengt Samuelsson as the chief scientist, indicating a strong emphasis on scientific expertise [1] - According to Tianyancha, the legal representative, chairman, and manager of Beirisen is Gu Ming, with a registered capital of 11.11 million yuan, and the top three shareholders are Gu Ming, Gao Min, and Jan Christer Janson, holding 67.54%, 7.02%, and 5.85% of the shares respectively [4]